Literature DB >> 16787500

Hemizygous/homozygous and heterozygous JAK2 mutation detected in plasma of patients with myeloproliferative diseases: correlation with clinical behaviour.

W Ma, H Kantarjian, S Verstovsek, I Jilani, M Gorre, F Giles, J Cortes, S O'Brien, M Keating, M Albitar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16787500     DOI： 10.1111/j.1365-2141.2006.06174.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  2 in total

1.  Plasma quantitation of JAK2 mutation is not suitable as a clinical test: an artifact of storage.

Authors:  Mohamed E Salama; Sabina I Swierczek; Kimberly Hickman; Andrew Wilson; Josef T Prchal
Journal:  Blood       Date:  2009-07-02       Impact factor: 22.113

2.  JAK2 exon 14 deletion in patients with chronic myeloproliferative neoplasms.

Authors:  Wanlong Ma; Hagop Kantarjian; Xi Zhang; Xiuqiang Wang; Zhong Zhang; Chen-Hsiung Yeh; Susan O'Brien; Francis Giles; Jean Marie Bruey; Maher Albitar
Journal:  PLoS One       Date:  2010-08-13       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.